The Role of Self-Nanoemulsifying Drug Delivery Systems of CDODA-Me in Sensitizing Erlotinib-Resistant Non–Small Cell Lung Cancer

Ebony Nottingham, Vasanthakumar Sekar, Arindam Mondal, Stephen Safe, Arun K. Rishi, Mandip Singh

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

We have investigated the effects of combination treatment involving ERL (erlotinib) with a glycyrrhetinic acid analog, CDODA-Me in overcoming ERL resistance, providing efforts to improve the oral bioavailability of this treatment using self-nanoemulsifying drug delivery systems (SNEDDS). A Qbd (quality-by-design) approach was used to prepare CDMS (CDODA-SNEDDS, 2 μΜ), which was characterized using surface response methodology to optimize drug content, particle size, and drug release. CDMS/ERL combinations showed synergism in wild-type and resistant H1975 and HCC827 cell lines with combination index values less than 1. Increased apoptosis, mitochondrial membrane potential depletion, and enhanced intracellular ROS levels were also observed in combination therapy. Western blot analysis showed that combination therapy inhibited phosphorylation of epidermal growth factor receptor (EGFR) (p < 0.01 in all cell lines) and Met receptor tyrosine kinase (MET) (p < 0.01 in all cell lines). In vivo, the relative bioavailability of CDMS increased significantly from 22.13 to 151.76 μg/mL compared to the dosing of oral suspension (dose equivalent). Our results demonstrate that combination therapy involving ERL and CDODA-Me overcomes resistance through dual inhibition of p-EGFR and p-MET leading to the induction of apoptosis, intracellular ROS accumulation, and decreased mitochondrial potential. Furthermore, CDMS improved the oral bioavailability of CDODA-Me.

Original languageEnglish (US)
Pages (from-to)1867-1882
Number of pages16
JournalJournal of Pharmaceutical Sciences
Volume109
Issue number6
DOIs
StatePublished - Jun 2020
Externally publishedYes

Keywords

  • combination therapy
  • drug resistance
  • epidermal growth factor receptor
  • erlotinib
  • non-small cell lung cancer
  • self nano-emulsifying drug delivery system

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'The Role of Self-Nanoemulsifying Drug Delivery Systems of CDODA-Me in Sensitizing Erlotinib-Resistant Non–Small Cell Lung Cancer'. Together they form a unique fingerprint.

Cite this